SCHEMBL26206444

SCHEMBL26206444

Cc1cc(CCCC(=O)O)c(Cl)c(OC[C@@H](C)CCC(N)=O)c1

nearest known ligand 0.36

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ PTGER1 P34995 2/20 0.36
▸ PTGER4 P35408 1/20 0.36
▸ PTGER3 P43115 1/20 0.36
▸ PTGER2 P43116 1/20 0.36
▸ CSF3R Q99062 1/20 0.36
▸ TSHR P16473 1/20 0.34
▸ FOS P01100 2/20 0.34
▸ JUN P05412 2/20 0.34
▸ PPARG P37231 1/20 0.34
▸ FFAR4 Q5NUL3 3/20 0.34
▸ FFAR1 O14842 2/20 0.34
▸ MCL1 Q07820 2/20 0.33
▸ KDM4E B2RXH2 1/20 0.32
▸ ALDH1A1 P00352 1/20 0.32
▸ HPGD P15428 1/20 0.32
▸ HSD17B10 Q99714 1/20 0.32
▸ GAA P10253 1/20 0.32
▸ PLA2G2A P14555 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26205873 0.90 MAPT (0.37) PTGER1KDM4EALDH1A1HPGDHSD17B10
SCHEMBL27015304 0.90 PTGER1 (0.33) PTGER1KDM4EALDH1A1HPGDHSD17B10
SCHEMBL26206383 0.87 FOS (0.36) PTGER1PTGER4PTGER3PTGER2CSF3R
SCHEMBL26206390 0.84 LTB4R (0.40) PTGER1PTGER4PTGER3PTGER2CSF3R
SCHEMBL26206385 0.83 FOS (0.36) PTGER1PTGER4PTGER3PTGER2CSF3R
SCHEMBL26206433 0.83 F13A1 (0.37) PTGER1PTGER4PTGER3PTGER2CSF3R
SCHEMBL26206391 0.81 LTB4R (0.44) PTGER1PTGER4PTGER3PTGER2FOS
SCHEMBL27015526 0.81 LTB4R (0.44) PTGER1PTGER4PTGER3PTGER2FOS
SCHEMBL23832934 0.80 AAK1 (0.42) PTGER1PTGER4PTGER3PTGER2TSHR
SCHEMBL22525537 0.80 AAK1 (0.42) PTGER1PTGER4PTGER3PTGER2TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240016942-A1 STAT DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2024-01-18 — — US disclosed
US-11746120-B2 Stat degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2023-09-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11746120-B2 Stat degraders and uses thereof STAT4, STAT1, STAT3 PTGER1 2776/4885PTGER4 2085/4885PTGER3 2989/4885
US-20240016942-A1 STAT DEGRADERS AND USES THEREOF STAT4, STAT1, STAT3 PTGER1 2776/4885PTGER4 2085/4885PTGER3 2989/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback